Lady Gaga AI biotech venture Outer Bio stepped out of stealth this week. The startup keeps donated human skin alive for four weeks, then trains machine learning models on how that tissue reacts.

Michael Polansky, the singer’s fiancé, co-founded the company and runs it as chief executive. Gaga, born Stefani Germanotta, sits on the board. Backers have committed roughly $23 million.

Lady Gaga AI Biotech Venture Turns Surgical Waste Into Training Data

Skin removed from the body normally dies within a week. Outer Bio’s platform, named Yuna, stretches that window to four weeks. Researchers can therefore track slow biology such as collagen breakdown, inflammation, and cellular aging.

Tissue reaches the lab within hours of surgery, mostly leftover material from cosmetic procedures. Donors span every age group, both sexes, and all six Fitzpatrick skin tones.

That matters because regulators have turned against the old default. The FDA issued a roadmap in April 2025 to cut unnecessary animal testing, then reported first-year progress this April. More than 90% of drugs that clear animal studies still fail in human trials, the agency notes.

Europe moved earlier. A full marketing ban has covered animal-tested cosmetics across the bloc since March 2013. Brands selling there have needed human alternatives ever since.

Polansky argues that simplified lab models flag toxicity without showing whether a compound actually works. Living tissue answers the harder question, because the drug meets the organ it targets. Slow damage and slow repair both become visible.

So far, the platform has logged more than 10,000 treatments across 300 donors, and each sample yields over 30,000 measurements. Published validation work shows Yuna reproducing inflammation, aging, and sun damage.

Subscribe to our YouTube channel to watch leaders and journalists provide expert insights

Silicon Valley Bets on Data It Cannot Compute

Polansky started the company quietly in 2022, after years running Sean Parker’s family office. He argues that biology, not compute, now caps progress in AI.

“AI models are improving far faster than the experiments that validate and train them.”

Michael Polansky, co-founder and CEO of Outer Bio, in the company’s announcement.

Investors in the Lady Gaga AI biotech startup include Wing Venture Capital, Initialized Capital, and SV Angel. Lightspeed Venture Partners joined too, alongside Polansky’s own firm, Hawktail.

That sum stays small next to the rest of the field. Chai Discovery collected $400 million in July for AI molecular design. OpenEvidence took $250 million in January.

Scarce biological data keeps drawing that money. Pfizer and Anthropic already treat AI in healthcare as core infrastructure, while crypto fortunes bankroll crypto-funded anti-aging studies. Meanwhile, Midjourney’s medical scanner chases a billion body scans a year.

Ownership of that data matters as much as the models. Elon Musk feeds SpaceX engineering data into Grok, and Amazon enrolled Twitch creator archives into AI training by default.

Outer Bio now sells platform access to biopharma teams and consumer brands. However, the harder test comes later. Skincare has gained just one proven anti-aging mechanism in three decades, and richer data alone will not change that.

Source: BeInCrypto